Regulatory Registration & Compliance for Malaysia
NPRA & MOH compliance, handled end-to-end.
We get food supplements, cosmetics, health products and medical devices compliant and registered with Malaysia’s NPRA and MOH — so paperwork never holds up your launch.
Two services, one regulatory partner:
Compliance Review
Before you register or list, we check your formulation, claims, packaging and labelling against NPRA / MOH rules — and tell you exactly what to fix.
- ✓ Formulation review against NPRA / MOH permissible-ingredient lists
- ✓ Label & claim check — health, therapeutic, prohibited phrases
- ✓ Packaging artwork compliance assessment
- ✓ Written compliance advisory report with recommended amendments
- ✓ Regulatory classification recommendation
Regulatory Registration
We manage the full NPRA registration process for your category — from dossier to approved registration.
- ✓ Dossier screening & bioequivalence desktop audit (oral solid generics)
- ✓ Submission of the dossier to NPRA
- ✓ Correspondence with NPRA to resolve queries & gap analysis
- ✓ Dossier templates & submission guidelines provided
Transparent pricing — PriooCare service fee plus government fees reimbursed at cost.
Get Your Product Registered
Why regulatory compliance matters in Malaysia
Malaysia's healthcare regulatory framework is governed by the Sale of Drugs Act 1952, the Control of Drugs and Cosmetics Regulations 1984, and the Medical Device Act 2012. Non-compliance carries financial penalties and can stall product launches by many months — a single missed approval can trigger import seizures at customs.
PriooCare's regulatory affairs team handles the full submission lifecycle so brands can focus on commercial execution. We've processed more than 100 marketing authorisations across pharmaceutical, supplement, cosmetic and medical device categories.
Our regulatory process
- Gap analysis — we review your product files against current NPRA / MDA requirements and identify documentation gaps before submission.
- Dossier preparation — our team compiles the technical dossier in the required structure (CTD modules for pharmaceuticals, MDA template for devices).
- Submission and tracking — we submit through Quest 3+ (NPRA) or MeDC@St (MDA) and provide regular status updates.
- Response handling — we respond to NPRA / MDA queries within deadlines, coordinating with your technical team as needed.
- Post-approval support — variation submissions, renewal handling and pharmacovigilance reporting.
Typical timelines
| Product type | Typical timeline | Authority |
|---|---|---|
| Cosmetic notification (NOT) | ~8 weeks | NPRA |
| Health supplement | 11–15 months | NPRA |
| Traditional product | 9–12 months | NPRA |
| Medical device (Class A) | Typically a few weeks | MDA |
| Medical device (Class B/C/D) | Class-dependent | MDA |
| GDPMD certification | Several months | MDA |
| MAL application (pharmaceutical) | Up to 21 months | NPRA / DCA |
Specific timelines vary by product category, dossier completeness and NPRA / MDA caseload. We give you an honest estimate after the gap analysis.
Frequently Asked Questions
For most product categories, yes — a locally registered Establishment Licence holder is required. PriooCare can act as your Authorised Representative or help you set up a local entity.
NOT (Notification) is for cosmetics — a notification-based process. MAL (Marketing Authorisation) is for pharmaceuticals and selected health supplements — a full evaluation involving safety, efficacy and quality review.
Yes. We work with the ASEAN Common Technical Dossier (ACTD) format and can coordinate with regulatory partners across the region for multi-market launches.
We analyse the rejection grounds, address the deficiencies and re-submit. Most rejections relate to documentation gaps, label compliance or stability data — fixable issues, not fundamental product problems.
Around 8 weeks for a standard NOT submission, assuming complete documentation. We do a gap analysis upfront to prevent delay-causing resubmissions.
Natural products and health supplements, cosmetics, food, pharmaceutical generics and medical devices — across NPRA and MDA pathways.